Tolerability & long-term disease control by IGHV mutation status among CLL patients on ibrutinib arm of E1912
Recommended Citation
Shanafelt TD, Wang XV, Hanson CA, et al. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912. Blood Adv. 2025;9(1):224-228. doi:10.1182/bloodadvances.2024013474
Type
Article
PubMed ID
39163612
Affiliations
Aurora Health Care, Mount Pleasant